Health Care Equipment

Tandem Diabetes

Tandem Diabetes released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 247.22 M (forecast USD 240.52 M), actual EPS USD -0.3 (forecast USD -0.4384)

Tandem Diabetes to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 240.54 M, EPS USD -0.4384

Tandem Diabetes Care Shifts to Pharmacy Channel, Offering Free Insulin Pumps

Tandem Diabetes released FY2025 Q4 earnings on February 19 After-Market (EST), actual revenue USD 290.38 M (forecast USD 277.24 M), actual EPS USD -0.0086 (forecast USD -0.0641)

Tandem Diabetes released FY2025 earnings on February 19 After-Market EST, actual revenue USD 1.015 B (forecast USD 1.001 B), actual EPS USD -3.0424 (forecast USD -2.8515)

Tandem Diabetes to Release FY2025 Q4 Earnings on February 19 After-Market EST, Forecast Revenue USD 277.24 M, EPS USD -0.0641

Tandem Diabetes Care Inc. Launches Tandem t:slim Mobile App in Canada

Baird Upgrades Tandem Diabetes Care Rating to Outperform with a Price Target of $30

Bernstein Analyst Maintains Hold Rating on Tandem Diabetes Care

Morgan Stanley Raises Tandem Diabetes Care's Target Price to $17.00

Tandem Diabetes Care Inc. Receives FDA Approval for Android Version of Tandem Mobi Mobile App

Stifel Nicolaus Reiterates Hold Rating on Tandem Diabetes Care

William Plovanic Maintains Buy Rating on Tandem Diabetes Care

Analyst Maintains Tandem Diabetes Care Hold Rating

Tandem Diabetes released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 249.25 M (forecast USD 235.77 M), actual EPS USD -0.3128 (forecast USD -0.36)

Tandem Diabetes released FY2025 9 Months Earnings on November 6 After-Market EST, with actual revenue of USD 724.35 M and actual EPS of USD -3.0604

Tandem Diabetes to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 235.77 M, EPS USD -0.36

Stifel Nicolaus Rates Tandem Diabetes Care as Hold

Kratky Recommends Edwards Lifesciences Stock, RBC Capital Gives Tandem Diabetes Care a Buy Rating

Wuensch Recommends Healthcare Stocks, Tandem Diabetes Care Receives Hold Rating

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

Micware

BiomX

MicroAlgo

MetaVia

Quantum Cyber NV

TNDM

SBIO

Tandem Diabetes Care announced the termination of Executive VP Mark Novara, effective May 18, 2026, while affirming that its strategy and 2026 goals remain unchanged. This leadership change may raise concerns among investors regarding sales execution, but the company aims to reassure stakeholders of its operational continuity. The latest analyst rating for TNDM stock is a Buy with a $31.00 price target, although concerns about balance-sheet risk and profitability persist.

Tip Ranks

iShares US Medical Devices

SPDR S&P Health Equip

ALPS Medical Breakthrough

Tandem Diabetes Care Announces Leadership Change, Strategy Unchanged

AORT

FIGS

HUBS

REAL

UPWK

Artivion(AORT) fell 28.26%, with a trading turnover 127.8 Million USD, and a year-to-date fell 44.3%. Figs(FIGS) fell 24.33%, with a trading turnover 132.2 Million USD, and a year-to-date rose 2.4%. CloudFlare(NET) fell 23.62%, with a trading turnover 3.8 Billion USD, and a year-to-date fell 0.5%.

Top Gainers&Losers

Artivion

Figs

CloudFlare

DXC Tech

Kodiak Robotics

HubSpot

Caris Life Sciences

The RealReal

Upwork

Top 10 US Stock Losers (5.8)

LABU

Analyst Mathew Blackman of TD Cowen has reaffirmed a Buy rating on Tandem Diabetes Care, maintaining a price target of $28. The decision is based on strengthening fundamentals, including first-quarter revenue exceeding expectations and improved margins. Despite supply constraints, the company shows a positive outlook with a planned regulatory submission for the Mobi tubeless product in 2026. Another report from Rothschild & Co Redburn also supports a Buy rating with a higher price target of $45.

iShares Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Zimmer Biomet

Orthofix

Buy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target Maintained

Tandem Diabetes Care shares are trading higher after the company reported better-than-expected Q1 financial results.

benzinga_article

GMED

CTKB

In Thursday's after-market session, several health care stocks experienced significant movements. Maravai LifeSciences (MRVI) rose 18.5% to $4.67, while Progyny (PGNY) increased by 14.56% to $21.95. Tandem Diabetes Care (TNDM) saw a 12.12% rise to $20.71. Conversely, Artivion (AORT) fell 20.9% to $28.0, and Arcturus Therapeutics (ARCT) declined by 19.11% to $7.2. Other notable gainers included Accuray (ARAY) and Globus Medical (GMED), while losers included Cytek Biosciences (CTKB) and Caris Life Sciences (CAI). All companies reported Q1 earnings today.

Tandem Diabetes(TNDM.US)

Tandem Diabetes Care Announces Leadership Change, Strategy Unchanged

Top 10 US Stock Losers (5.8)

Buy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target Maintained

Tandem Diabetes Care shares are trading higher after the company reported better-than-expected Q1 financial results.

12 Health Care Stocks Moving In Thursday's After-Market Session

Tandem Diabetes | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 247.22 M